Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Briacell Therapeutics Corp (BCT.TO)

Briacell Therapeutics Corp (BCT.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BCT.TO : 0.89 (-1.11%)
BCTXW : 0.2723 (-9.23%)
BCTX : 0.6500 (-3.99%)
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

BCT.TO : 0.89 (-1.11%)
BCTXW : 0.2723 (-9.23%)
BCTX : 0.6500 (-3.99%)
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BCT.TO : 0.89 (-1.11%)
BCTXW : 0.2723 (-9.23%)
BCTX : 0.6500 (-3.99%)
Stocks in play: BriaCell Therapeutics Corp.

Provided a clinical engagement update of its pivotal Phase 3 study of Bria-IMTâ„¢ in combination with ...

BCT.TO : 0.89 (-1.11%)
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

BCT.TO : 0.89 (-1.11%)
BCTXW : 0.2723 (-9.23%)
BCTX : 0.6500 (-3.99%)
Stocks in play: BriaCell Therapeutics Corp.

Announced U.S. FDA authorization of an Expanded Access Policy (EAP) for metastatic breast cancer (MBC) ...

BCT.TO : 0.89 (-1.11%)
Stocks in play: BriaCell Therapeutics Corp.

Announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, ...

BCT.TO : 0.89 (-1.11%)
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 13, 2023 – USA News Group  –  Sufferers of many different ailments saw reason to grow their hope in 2022 when...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.55 (+4.03%)
FULC : 3.64 (unch)
RNA : 46.73 (-0.83%)
BCTX : 0.6500 (-3.99%)
BCT.TO : 0.89 (-1.11%)
GILD : 94.35 (-2.76%)
Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of...

LLY : 818.86 (-1.63%)
PBYI : 3.21 (-2.73%)
GILD : 94.35 (-2.76%)
IMGN : 31.23 (unch)
BCTX : 0.6500 (-3.99%)
BCT.TO : 0.89 (-1.11%)
Stocks in play: BriaCell Therapeutics Corp.

Announced that it has entered into an arrangement agreement dated May 24, 2023 with BriaPro Therapeutics ...

BCT.TO : 0.89 (-1.11%)

Barchart Exclusives

1 Dividend Aristocrat to Bet on Trump's Tariffs and the Fed's Rate Cuts
Nucor is one stock that stands to benefit from the Fed's rate cuts as well as any possible tariffs under a Trump administration. It is also a dividend aristocrat, and has increased its payouts for over 5 decades. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar